series-b
Stage
1
Investors
About
HistoRx develops tissue-based diagnostic assays using AQUA technology that quantitatively measure protein biomarkers in tissue samples, aiding clinical decision-making in cancer diagnosis and treatment, including a melanoma assay licensed from Yale University to assess recurrence risk in node-negative patients.
Explore HistoRx's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.